GlassScriptPhysician profile
Jason W Guin
NPI 1134129620
$803.13
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.76 · 2020: $24.65 · 2021: $38.56 · 2022: $378 · 2023: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $227.82 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $187.05 | 2019-2023 | Dupixent |
| Kaleo, INC. | $125.59 | 2021-2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $56.40 | 2019-2023 | Symbicort |
| Biocryst US Sales Co., LLC | $55.17 | 2022-2023 | Orladeyo |
| Glaxosmithkline, LLC. | $46.37 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.97 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Pharming Healthcare, INC. | $18.23 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.24 | 2022 | |
| Pfizer INC. | $14.91 | 2023 | |
| Amgen INC. | $14.38 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Guin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.